Fig. 5

Impact of TN on 5-year DFS of patients with current pathological stage I and II tumors. A The pathological stage of patients who had stage I tumors and high-risk TN were up-regulated because their 5-year DFS was comparable to patients who had stage II tumors in the training set, suggesting that the patients who had high-risk TN and stage I tumors should be incorporated into stage II (stage II-n), while the patients who had low-risk TN and stage I tumors should remain in stage I (stage I-n). B The same results in (A) were validated in the validation set. C The pathological stage of patients who had stage II tumors and high-risk TN were up-regulated because their 5-year DFS was comparable to patients who had stage III tumors in the training set, suggesting that the patients who had high-risk TN and stage II tumors should be incorporated into stage III (stage III-n), while the patients who had low-risk TN and stage II tumors should remain in stage II (stage II-n). D The same results in (C) were validated in the validation set